A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.

Trial Profile

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Nivolumab (Primary) ; NKTR 214 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PIVOT; PIVOT-02; PIVOT-04
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 20 Sep 2017 According to a Nektar Therapeutics media release, enrollment of the dose-escalation stage is completed and ongoing in the expansion cohort stage.
    • 20 Sep 2017 According to a Nektar Therapeutics media release, the company will present data from this study at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2017.
    • 12 Sep 2017 Trial design presented at the 42nd European Society for Medical Oncology Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top